UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 7, 2015
ENTELLUS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
0001-36814 |
|
20-4627978 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
3600 Holly Lane North, Suite 40
Plymouth, Minnesota 55447
(Address of principal executive offices) (Zip Code)
(763) 463-1595
(Registrants telephone number, include area code)
N/A
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On May 7, 2015, Entellus Medical, Inc. announced its financial results for the three months ended March 31, 2015. The full text of the press release
issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including
Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Press Release issued on May 7, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ENTELLUS MEDICAL, INC. |
|
|
|
|
Date: May 7, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Thomas E. Griffin |
|
|
|
|
|
|
Thomas E. Griffin |
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Press Release issued on May 7, 2015 |
Exhibit 99.1
Contact: Leigh Salvo
415-513-1281
ir@entellusmedical.com
ENTELLUS MEDICAL ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS
UPDATES 2015 FINANCIAL OUTLOOK
PLYMOUTH, MN. (May 7, 2015) Entellus Medical, Inc. (Entellus Medical or the Company) (NASDAQ: ENTL), a medical
technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial
results for the three months ended March 31, 2015.
Recent Highlights and Accomplishments
|
|
|
Achieved revenue of $13.5 million in the first quarter of 2015, an increase of 33% versus the first quarter of 2014 |
|
|
|
Commercially launched XprESS Ultra Multi-Sinus Dilation System with positive clinician response |
|
|
|
Expanded field sales organization to 110 as of March 31, 2015 |
Our first quarter results saw growth
balanced across the operating room and office-based settings. We are off to a promising start in 2015 and remain well positioned to expand the market for office-based treatment of patients suffering from sinusitis and to provide our highly
efficacious solution that reduces costs to the healthcare system and to patients. Physician reception to our release of the XprESS Ultra Multi-Sinus Dilation System has been strong as broad awareness and utilization of our XprESS family of products
continues to grow, said Robert White, President and Chief Executive Officer.
First Quarter 2015 Financial Results
Revenue for the three months ended March 31, 2015 increased 33% to $13.5 million from $10.2 million during the same period of the prior year. The growth
in revenue was primarily attributable to an increase of approximately $3.2 million in sales of the XprESS family of products.
Gross margin for the first
quarter of 2015 increased to 78.2%, compared to 77.4% for the same period in 2014. Operating expenses for the first quarter of 2015 were $14.0 million, an increase of 40% compared to $10.0 million for the same period of the prior year. The increase
in gross margin was primarily due to an increase in revenue per procedure and increased unit sales. The increase in operating expenses was primarily due to compensation and other employee-related expenses resulting from increased headcount in our
sales, finance, and IT staff as well as the cost of being a public company.
Net loss for the three months ended March 31, 2015 was $4.3 million, or
$0.35 per diluted share, compared with net loss of $2.5 million, or $1.80 per diluted share, for the three months ended March 31, 2014.
Entellus
Medical ended the first quarter of 2015 with $78.4 million in cash, cash equivalents and short-term investments.
2015 Financial Outlook
Entellus Medical estimates that second quarter 2015 revenue will range from approximately $14.8 million to $15.3 million, which would represent growth of
approximately 18% to 22% versus the second quarter of 2014. The Company expects that gross margin for the second quarter of 2015 will range from 77.5% to 78.5% compared to 78.3% in the second quarter of 2014. Second quarter operating expenses are
expected to be in the range of $14.3 million to $15.3 million, with the increase primarily due to sales and marketing expenses related to the expansion of the U.S. sales organization, and from general and administrative expenses associated with the
expense of operating as a public company. Second quarter net loss is estimated to range from approximately $2.8 million to $4.3 million, or an estimated net loss of $0.15 to $0.23 per share. The estimated net loss for the second quarter includes
estimated non-cash stock-based compensation of $0.7 million to $0.8 million. The number of weighted average shares outstanding used to calculate estimated earnings per share for the second quarter is currently expected to range from approximately
18.7 million to 18.8 million.
Entellus Medical continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million,
representing growth of 20% to 25% annually and that gross margin will be in a range of 77% to 78% for 2015. The Company now expects operating expenses to be in a range of $59 million to $62 million, including estimated charges for stock-based
compensation expenses of $2.5 million to $2.7 million. This compares to the Companys previous operating expense expectation for 2015 of $60 million to $63 million. Full year 2015 net loss is now expected to be in a range of $14.0 million to
$19.0 million, or a net loss of $0.80 to $1.10 per share. This compares to the Companys previous expectations for net loss in the range of $14.6 million to $20.0 million, or a net loss of $0.84 to $1.17 per share. This expected net loss per
share assumes approximately 17.2 million to 17.4 million weighted average shares outstanding for the year.
Webcast and Conference Call
Information
The Companys management team will host a corresponding conference call beginning today at 1:30pm PT/4:30pm ET to discuss the
financial results and recent business developments. Individuals interested in listening to the conference call may do so by dialing (877) 930-5751 for domestic callers or (253) 336-7277 for international callers, using Conference ID:
22992710. To listen to a live webcast, please visit the investor relations section of the Entellus Medical website at: www.entellusmedical.com.
A
replay of the call will be available beginning May 7, 2015 at 4:30pm PT/7:30pm ET through midnight on May 8, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 22992710. The webcast
will also be available on the Entellus website for one month following the completion of the call.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of
chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a
stand-alone therapy, Entellus Medicals balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or
FESS. Patients treated with Entellus Medicals products in this trial in the ENT physician office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than
patients receiving FESS. Entellus Medical currently markets its products in the United States and Canada and sells its products through a direct sales force in the United States.
Forward-Looking Statements
All statements contained in
this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without
limitation, statements regarding the Companys financial outlook and
are based on managements current expectations and involve known and unknown risks and uncertainties that may cause Entellus Medicals actual financial results, performance or
achievements to be materially different from any estimated or forecasted future financial results, performance or achievements expressed or implied by the forward looking statements. Such risks and uncertainties include, among others, the
Companys significant operating expenses incurred since inception and expected to incur in the future; its dependence on a limited number of products, including the XprESS family of multi-sinus products; physicians willingness to change
current practices and continue to adopt office-based balloon sinus dilation procedures; inability to maintain adequate levels of coverage and reimbursement for the procedures using the Companys products; the impact of competition within the
industry; the Companys dependence on a key license agreement; and the Companys ability to establish and maintain intellectual property protection for its products. Other factors that could cause actual results to differ materially from
those contemplated by the forward looking statements in the Companys comments today can be found under the caption Risk Factors in the Companys Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commission, or SEC, and its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward looking statements, even if subsequent events cause our views to change.
Entellus Medical, Inc.
Condensed Statement of Operations
(in thousands, except per share data)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2015 |
|
|
2014 |
|
Revenue |
|
$ |
13,502 |
|
|
$ |
10,175 |
|
Cost of goods sold |
|
|
2,949 |
|
|
|
2,298 |
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
10,553 |
|
|
|
7,877 |
|
Gross margin |
|
|
78.2 |
% |
|
|
77.4 |
% |
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Selling and marketing |
|
|
9,887 |
|
|
|
7,722 |
|
Research and development |
|
|
1,300 |
|
|
|
1,116 |
|
General and administrative |
|
|
2,816 |
|
|
|
1,158 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
14,003 |
|
|
|
9,996 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(3,450 |
) |
|
|
(2,119 |
) |
Other expense, net |
|
|
(898 |
) |
|
|
(416 |
) |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,348 |
) |
|
$ |
(2,535 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(0.35 |
) |
|
$ |
(1.80 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares used to compute net loss per share, basic and diluted |
|
|
12,542 |
|
|
|
1,412 |
|
|
|
|
|
|
|
|
|
|
Entellus Medical, Inc.
Condensed Balance Sheet
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Assets |
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
19,732 |
|
|
$ |
3,484 |
|
Short-term investments |
|
|
58,653 |
|
|
|
|
|
Accrued interest income |
|
|
248 |
|
|
|
|
|
Accounts receivable, net |
|
|
8,424 |
|
|
|
8,746 |
|
Inventories |
|
|
2,596 |
|
|
|
2,439 |
|
Prepaid expenses and other current assets |
|
|
1,203 |
|
|
|
883 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
90,856 |
|
|
|
15,552 |
|
Property and equipment, net |
|
|
2,097 |
|
|
|
1,730 |
|
Other non-current assets |
|
|
4,199 |
|
|
|
1,954 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
97,152 |
|
|
$ |
19,236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity (deficit) |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,042 |
|
|
$ |
2,414 |
|
Current portion of long-term debt |
|
|
1,002 |
|
|
|
|
|
Preferred stock warrant liability |
|
|
|
|
|
|
291 |
|
Accrued expenses |
|
|
5,677 |
|
|
|
5,084 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
8,721 |
|
|
|
7,789 |
|
Long-term liabilities |
|
|
|
|
|
|
|
|
Long-term debt |
|
|
18,998 |
|
|
|
20,000 |
|
Other non-current liabilities |
|
|
325 |
|
|
|
247 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
28,044 |
|
|
|
28,036 |
|
Convertible preferred stock |
|
|
|
|
|
|
91,554 |
|
Total stockholders equity (deficit) |
|
|
69,108 |
|
|
|
(100,354 |
) |
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity (deficit) |
|
$ |
97,152 |
|
|
$ |
19,236 |
|
|
|
|
|
|
|
|
|
|
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024